FINACEA® Plus™
Dermatology healthcare professionals agree on the importance of adding effective skin care to the successful management of rosacea. The skin of the rosacea patient, especially when it is treated with topical medications, needs to be gently cleansed and moisturized. FINACEA® Plus™ can help these patients do that easily and effectively.
FINACEA® Plus™ packages together FINACEA®, the first FDA-approved prescription gel for treating lesions and erythema associated with mild to moderate rosacea, with 3 oz bottles of CeraVe® Moisturizing Lotion and CeraVe® Hydrating Cleanser. Putting these three components in one convenient package offers patients an easy way to help manage their symptoms and take good care of their skin. CeraVe® Hydrating Cleanser provides gentle, effective cleansing while it restores and enhances the skin barrier. CeraVe® Moisturizing Lotion is uniquely formulated to increase the skin’s ability to attract, hold and distribute moisture.
INDICATIONS & USAGE
Finacea is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.
IMPORTANT SAFETY INFORMATION
Finacea is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. Finacea is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety - Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with a dark complexion, these patients should be monitored for early signs of hypopigmentation.
